Kezar Life Sciences, Inc. 8-K

What Happened

• On March 6, 2026 Kezar Life Sciences (KZR) entered an asset purchase agreement with Enodia Therapeutics SAS under which Enodia acquired Kezar’s Sec61‑based discovery and development program assets, including the product candidate internally known as KZR‑261. The Company disclosed the transaction in an 8‑K filed March 12, 2026 and issued a joint press release with Enodia the same day.
• Kezar received $800,000 in cash at closing and is due an additional $200,000 upon delivery of certain inventory or 45 days after closing (whichever is earlier). Kezar is also eligible for up to $127,000,000 in milestone payments and will receive single‑digit tiered royalties on net sales of products developed from the acquired assets.

Key Details

• Agreement date: March 6, 2026; press release/8‑K filed March 12, 2026.
• Near‑term cash: $800,000 at closing + $200,000 contingent (≈ $1.0M total near term).
• Potential future consideration: up to $127,000,000 in development/regulatory/commercial milestones + single‑digit tiered royalties (subject to reductions for patent expiry, generics and third‑party license payments).
• Scope: Enodia acquired only the Sec61 program assets (including KZR‑261) and assumed related liabilities; Kezar retained its zetomizomib program, employees, cash, receivables, real property and equipment.
• Indemnities: Mutual indemnification provisions with non‑fraud liability recoveries capped at $1,000,000 for each party; covenants by Kezar on conduct of business lasting until the earlier of a change of control or five years after closing.

Why It Matters

• The agreement monetizes Kezar’s Sec61 program, providing a small immediate cash inflow and the potential for significant future upside through milestones and royalties if Enodia advances and commercializes products from the assets.
• Kezar retains its zetomizomib program and core assets, so this is a sale/divestiture of a specific asset set rather than a company sale; investors should note the limited immediate cash impact versus the contingent nature of most consideration.
• The transfer shifts development responsibility—and related liabilities—for the Sec61 program to Enodia (subject to the stated indemnities and caps), which could change Kezar’s future R&D focus and expense profile.